97 related articles for article (PubMed ID: 24020866)
1. Pharmacological challenge with naloxone and cue exposure in alcohol dependence: results of a randomized, double-blind placebo-controlled trial.
Lieb M; Palm U; Chiang S; Laubender RP; Nothdurfter C; Sarubin N; Mokhtari-Nejad R; Koller G; Soyka M
World J Biol Psychiatry; 2013 Sep; 14(7):539-46. PubMed ID: 24020866
[TBL] [Abstract][Full Text] [Related]
2. Confirmation that offspring from families with alcohol-dependent individuals have greater hypothalamic-pituitary-adrenal axis activation induced by naloxone compared with offspring without a family history of alcohol dependence.
Wand G; McCaul ME; Gotjen D; Reynolds J; Lee S
Alcohol Clin Exp Res; 2001 Aug; 25(8):1134-9. PubMed ID: 11505044
[TBL] [Abstract][Full Text] [Related]
3. The Impact of the Opioid Antagonist Naloxone on Experimentally Induced Craving in Nicotine-Dependent Individuals.
Krause D; Warnecke M; Schuetz CG; Soyka M; Manz KM; Proebstl L; Kamp F; Chrobok AI; Pogarell O; Koller G
Eur Addict Res; 2018; 24(5):255-265. PubMed ID: 30423575
[TBL] [Abstract][Full Text] [Related]
4. Adrenocorticotropin responses to naloxone in sons of alcohol-dependent men.
Wand GS; Mangold D; Ali M
J Clin Endocrinol Metab; 1999 Jan; 84(1):64-8. PubMed ID: 9920063
[TBL] [Abstract][Full Text] [Related]
5. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.
O'Malley SS; Krishnan-Sarin S; Farren C; Sinha R; Kreek MJ
Psychopharmacology (Berl); 2002 Feb; 160(1):19-29. PubMed ID: 11862370
[TBL] [Abstract][Full Text] [Related]
7. Adrenocortical responses and family history of alcoholism.
Wand GS; Mangold D; Ali M; Giggey P
Alcohol Clin Exp Res; 1999 Jul; 23(7):1185-90. PubMed ID: 10443984
[TBL] [Abstract][Full Text] [Related]
8. Variable dose naltrexone-induced hypothalamic-pituitary-adrenal stimulation in abstinent alcoholics: a preliminary study.
Farren CK; O'Malley S; Grebski G; Maniar S; Porter M; Kreek MJ
Alcohol Clin Exp Res; 1999 Mar; 23(3):502-8. PubMed ID: 10195825
[TBL] [Abstract][Full Text] [Related]
9. Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?
Kiefer F; Jahn H; Otte C; Naber D; Wiedemann K
Biol Psychiatry; 2006 Jul; 60(1):74-6. PubMed ID: 16483549
[TBL] [Abstract][Full Text] [Related]
10. The relationship between naloxone-induced cortisol and delta opioid receptor availability in mesolimbic structures is disrupted in alcohol-dependent subjects.
Wand GS; Weerts EM; Kuwabara H; Wong DF; Xu X; McCaul ME
Addict Biol; 2013 Jan; 18(1):181-92. PubMed ID: 22264217
[TBL] [Abstract][Full Text] [Related]
11. Family history of alcoholism and hypothalamic opioidergic activity.
Wand GS; Mangold D; El Deiry S; McCaul ME; Hoover D
Arch Gen Psychiatry; 1998 Dec; 55(12):1114-9. PubMed ID: 9862555
[TBL] [Abstract][Full Text] [Related]
12. Alcohol administration attenuates hypothalamic-pituitary-adrenal (HPA) activity in healthy men at low genetic risk for alcoholism, but not in high-risk subjects.
Mick I; Spring K; Uhr M; Zimmermann US
Addict Biol; 2013 Sep; 18(5):863-71. PubMed ID: 22260244
[TBL] [Abstract][Full Text] [Related]
13. A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence.
Wong CJ; Witcher J; Mallinckrodt C; Dean RA; Anton RF; Chen Y; Fijal BA; Ouyang H; Dharia S; Sundseth SS; Schuh KJ; Kinon BJ
Alcohol Clin Exp Res; 2014 Feb; 38(2):511-20. PubMed ID: 24010675
[TBL] [Abstract][Full Text] [Related]
14. The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.
Ooteman W; Koeter MW; Verheul R; Schippers GM; van den Brink W
Eur Neuropsychopharmacol; 2007 Jul; 17(8):558-66. PubMed ID: 17379484
[TBL] [Abstract][Full Text] [Related]
15. Cortisol and adrenocorticotropic hormone responses to naloxone in subjects with high and low neuroticism.
Mangold DL; Wand GS
Biol Psychiatry; 2006 Oct; 60(8):850-5. PubMed ID: 16950229
[TBL] [Abstract][Full Text] [Related]
16. Naloxone-induced pituitary-adrenal activation does not differ in patients with depression, obsessive compulsive disorder, and healthy controls.
Michelson D; Altemus M; Galliven E; Hill L; Greenberg BD; Gold P
Neuropsychopharmacology; 1996 Aug; 15(2):207-12. PubMed ID: 8840357
[TBL] [Abstract][Full Text] [Related]
17. High-dose naloxone (1.0 mg/kg): psychological and endocrine effects in normal male subjects pretreated with one milligram of dexamethasone.
Martín-Del-Campo AF; Cortés-Sotres J; Herrera-Ferrá K; Ulloa-Aguirre A
Psychoneuroendocrinology; 1998 May; 23(4):413-24. PubMed ID: 9695140
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
[TBL] [Abstract][Full Text] [Related]
19. The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects.
Schwandt ML; Cortes CR; Kwako LE; George DT; Momenan R; Sinha R; Grigoriadis DE; Pich EM; Leggio L; Heilig M
Neuropsychopharmacology; 2016 Nov; 41(12):2818-2829. PubMed ID: 27109623
[TBL] [Abstract][Full Text] [Related]
20. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS
Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
